<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32691043</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2083</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>16</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Human molecular genetics</Title><ISOAbbreviation>Hum Mol Genet</ISOAbbreviation></Journal><ArticleTitle>Lysine acetylation regulates the RNA binding, subcellular localization and inclusion formation of FUS.</ArticleTitle><Pagination><StartPage>2684</StartPage><EndPage>2697</EndPage><MedlinePgn>2684-2697</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/hmg/ddaa159</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the preferential death of motor neurons. Approximately 10% of ALS cases are familial and 90% are sporadic. Fused in sarcoma (FUS) is a ubiquitously expressed RNA-binding protein implicated in familial ALS and frontotemporal dementia (FTD). The physiological function and pathological mechanism of FUS are not well understood, particularly whether post-translational modifications play a role in regulating FUS function. In this study, we discovered that FUS was acetylated at lysine-315/316 (K315/K316) and lysine-510 (K510) residues in two distinct domains. Located in the nuclear localization sequence, K510 acetylation disrupted the interaction between FUS and Transportin-1, resulting in the mislocalization of FUS in the cytoplasm and formation of stress granule-like inclusions. Located in the RNA recognition motif, K315/K316 acetylation reduced RNA binding to FUS and decreased the formation of cytoplasmic inclusions. Treatment with deacetylase inhibitors also significantly reduced the inclusion formation in cells expressing ALS mutation P525L. More interestingly, familial ALS patient fibroblasts showed higher levels of FUS K510 acetylation as compared with healthy controls. Lastly, CREB-binding protein/p300 acetylated FUS, whereas both sirtuins and histone deacetylases families of lysine deacetylases contributed to FUS deacetylation. These findings demonstrate that FUS acetylation regulates the RNA binding, subcellular localization and inclusion formation of FUS, implicating a potential role of acetylation in the pathophysiological process leading to FUS-mediated ALS/FTD.</AbstractText><CopyrightInformation>Published by Oxford University Press 2020.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arenas</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Toxicology and Cancer Biology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Biochemistry.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuang</LastName><ForeName>Lisha</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Biochemistry.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnett</LastName><ForeName>Kelly R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Biochemistry.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasarskis</LastName><ForeName>Edward J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, University of Kentucky, Lexington, KY 40536, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gal</LastName><ForeName>Jozsef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Biochemistry.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Haining</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Toxicology and Cancer Biology.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Cellular Biochemistry.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lexington VA Medical Center, Research and Development, Lexington, KY 40502, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS115507</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS077284</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS095299</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM129325</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 ES007266</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR029127</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX002149</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>IS1 BX003561</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Mol Genet</MedlineTA><NlmUniqueID>9208958</NlmUniqueID><ISSNLinking>0964-6906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019913">Nuclear Localization Signals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C108121">TNPO1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D028961">beta Karyopherins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D037761">Sirtuins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.98</RegistryNumber><NameOfSubstance UI="D006655">Histone Deacetylases</NameOfSubstance></Chemical><Chemical><RegistryNumber>K3Z4F929H6</RegistryNumber><NameOfSubstance UI="D008239">Lysine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056572" MajorTopicYN="N">Histone Deacetylase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006655" MajorTopicYN="N">Histone Deacetylases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008239" MajorTopicYN="N">Lysine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019913" MajorTopicYN="N">Nuclear Localization Signals</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D037761" MajorTopicYN="N">Sirtuins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D028961" MajorTopicYN="N">beta Karyopherins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32691043</ArticleId><ArticleId IdType="pmc">PMC7530527</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddaa159</ArticleId><ArticleId IdType="pii">5874040</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wijesekera L.C. and Leigh P.N. (2009) Amyotrophic lateral sclerosis. Orphanet. J. Rare Dis., 4, 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H., Morino H., Ito H., Izumi Y., Kato H., Watanabe Y., Kinoshita Y., Kamada M., Nodera H., Suzuki H. &#xa0;et al. (2010) Mutations of optineurin in amyotrophic lateral sclerosis. Nature, 465, 223&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Hardiman O., Benatar M., Brooks B.R., Chio A., de Carvalho M., Ince P.G., Lin C., Miller R.G., Mitsumoto H. &#xa0;et al. (2013) Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol., 12, 310&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4565161</ArticleId><ArticleId IdType="pubmed">23415570</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Sayana P., Zhang X. and Le W. (2013) Genetics of amyotrophic lateral sclerosis: an update. Mol. Neurodegener., 8, 28&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766231</ArticleId><ArticleId IdType="pubmed">23941283</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski T.J. Jr., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T. &#xa0;et al. (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science, 323, 1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R.A., Neumann M., Bigio E.H., Cairns N.J., Alafuzoff I., Kril J., Kovacs G.G., Ghetti B., Halliday G., Holm I.E. &#xa0;et al. (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol., 119, 1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799633</ArticleId><ArticleId IdType="pubmed">19924424</ArticleId></ArticleIdList></Reference><Reference><Citation>Baechtold H., Kuroda M., Sok J., Ron D., Lopez B.S. and Akhmedov A.T. (1999) Human 75-kDa DNA-pairing protein is identical to the pro-oncoprotein TLS/FUS and is able to promote D-loop formation. J. Biol. Chem., 274, 34337&#x2013;34342.</Citation><ArticleIdList><ArticleId IdType="pubmed">10567410</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastrocola A.S., Kim S.H., Trinh A.T., Rodenkirch L.A. and Tibbetts R.S. (2013) The RNA-binding protein fused in sarcoma (FUS) functions downstream of poly(ADP-ribose) polymerase (PARP) in response to DNA damage. J. Biol. Chem., 288, 24731&#x2013;24741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3750169</ArticleId><ArticleId IdType="pubmed">23833192</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W.Y., Pan L., Su S.C., Quinn E.J., Sasaki M., Jimenez J.C., Mackenzie I.R., Huang E.J. and Tsai L.H. (2013) Interaction of FUS and HDAC1 regulates DNA damage response and repair in neurons. Nat. Neurosci., 16, 1383&#x2013;1391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5564396</ArticleId><ArticleId IdType="pubmed">24036913</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Arai S., Song X., Reichart D., Du K., Pascual G., Tempst P., Rosenfeld M.G., Glass C.K. and Kurokawa R. (2008) Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature, 454, 126&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823488</ArticleId><ArticleId IdType="pubmed">18509338</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan A.Y. and Manley J.L. (2010) TLS inhibits RNA polymerase III transcription. Mol. Cell. Biol., 30, 186&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798296</ArticleId><ArticleId IdType="pubmed">19841068</ArticleId></ArticleIdList></Reference><Reference><Citation>Du K., Arai S., Kawamura T., Matsushita A. and Kurokawa R. (2011) TLS and PRMT1 synergistically coactivate transcription at the survivin promoter through TLS arginine methylation. Biochem. Biophys. Res. Commun., 404, 991&#x2013;996.</Citation><ArticleIdList><ArticleId IdType="pubmed">21187067</ArticleId></ArticleIdList></Reference><Reference><Citation>Haile S., Lal A., Myung J.K. and Sadar M.D. (2011) FUS/TLS is a co-activator of androgen receptor in prostate cancer cells. PLoS One, 6, e24197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3164714</ArticleId><ArticleId IdType="pubmed">21909421</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan A.Y., Riley T.R., Coady T., Bussemaker H.J. and Manley J.L. (2012) TLS/FUS (translocated in liposarcoma/fused in sarcoma) regulates target gene transcription via single-stranded DNA response elements. Proc. Natl. Acad. Sci. U. S. A., 109, 6030&#x2013;6035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3341064</ArticleId><ArticleId IdType="pubmed">22460799</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz J.C., Ebmeier C.C., Podell E.R., Heimiller J., Taatjes D.J. and Cech T.R. (2012) FUS binds the CTD of RNA polymerase II and regulates its phosphorylation at Ser2. Genes Dev., 26, 2690&#x2013;2695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3533074</ArticleId><ArticleId IdType="pubmed">23249733</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujioka Y., Ishigaki S., Masuda A., Iguchi Y., Udagawa T., Watanabe H., Katsuno M., Ohno K. and Sobue G. (2013) FUS-regulated region- and cell-type-specific transcriptome is associated with cell selectivity in ALS/FTLD. Sci. Rep., 3, 2388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3737506</ArticleId><ArticleId IdType="pubmed">23925123</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronisz A., Carey H.A., Godlewski J., Sif S., Ostrowski M.C. and Sharma S.M. (2014) The multifunctional protein fused in sarcoma (FUS) is a coactivator of microphthalmia-associated transcription factor (MITF). J. Biol. Chem., 289, 326&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3879555</ArticleId><ArticleId IdType="pubmed">24257758</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhar S.K., Zhang J., Gal J., Xu Y., Miao L., Lynn B.C., Zhu H., Kasarskis E.J. and St Clair D.K. (2014) FUsed in sarcoma is a novel regulator of manganese superoxide dismutase gene transcription. Antioxid. Redox Signal., 20, 1550&#x2013;1566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3942683</ArticleId><ArticleId IdType="pubmed">23834335</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Gal J., Chen J. and Zhu H. (2014) Self-assembled FUS binds active chromatin and regulates gene transcription. Proc. Natl. Acad. Sci. U. S. A., 111, 17809&#x2013;17814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4273402</ArticleId><ArticleId IdType="pubmed">25453086</ArticleId></ArticleIdList></Reference><Reference><Citation>Uranishi H., Tetsuka T., Yamashita M., Asamitsu K., Shimizu M., Itoh M. and Okamoto T. (2001) Involvement of the pro-oncoprotein TLS (translocated in liposarcoma) in nuclear factor-kappa B p65-mediated transcription as a coactivator. J. Biol. Chem., 276, 13395&#x2013;13401.</Citation><ArticleIdList><ArticleId IdType="pubmed">11278855</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Embree L.J., Tsai S. and Hickstein D.D. (1998) Oncoprotein TLS interacts with serine-arginine proteins involved in RNA splicing. J. Biol. Chem., 273, 27761&#x2013;27764.</Citation><ArticleIdList><ArticleId IdType="pubmed">9774382</ArticleId></ArticleIdList></Reference><Reference><Citation>Dichmann D.S. and Harland R.M. (2012) Fus/TLS orchestrates splicing of developmental regulators during gastrulation. Genes Dev., 26, 1351&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3387662</ArticleId><ArticleId IdType="pubmed">22713872</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinszner H., Sok J., Immanuel D., Yin Y. and Ron D. (1997) TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J. Cell Sci., 110, 1741&#x2013;1750.</Citation><ArticleIdList><ArticleId IdType="pubmed">9264461</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii R. and Takumi T. (2005) TLS facilitates transport of mRNA encoding an actin-stabilizing protein to dendritic spines. J. Cell. Sci., 118, 5755&#x2013;5765.</Citation><ArticleIdList><ArticleId IdType="pubmed">16317045</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii R., Okabe S., Urushido T., Inoue K., Yoshimura A., Tachibana T., Nishikawa T., Hicks G.G. and Takumi T. (2005) The RNA binding protein TLS is translocated to dendritic spines by mGluR5 activation and regulates spine morphology. Curr. Biol., 15, 587&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">15797031</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton C.F., Tang A.A., Kulkarni A., West J., Brooks M., Stubblefield J.J., Liu Y., Zhang M.Q., Green C.B., Huber K.M. &#xa0;et al. (2014) Activity-dependent FUS dysregulation disrupts synaptic homeostasis. Proc. Natl. Acad. Sci. U. S. A., 111, E4769&#x2013;E4778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4226112</ArticleId><ArticleId IdType="pubmed">25324524</ArticleId></ArticleIdList></Reference><Reference><Citation>Sama R.R.K., Ward C.L. and Bosco D.A. (2014) Functions of FUS/TLS from DNA repair to stress response: implications for ALS. ASN Neuro, 6, 1759091414544472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4189536</ArticleId><ArticleId IdType="pubmed">25289647</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson M.K., Stahlberg A., Arvidsson Y., Olofsson A., Semb H., Stenman G., Nilsson O. and Aman P. (2008) The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. BMC Cell Biol., 9, 37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2478660</ArticleId><ArticleId IdType="pubmed">18620564</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco D.A., Lemay N., Ko H.K., Zhou H., Burke C., Kwiatkowski T.J. Jr., Sapp P., McKenna-Yasek D., Brown R.H. Jr. and Hayward L.J. (2010) Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum. Mol. Genet., 19, 4160&#x2013;4175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2981014</ArticleId><ArticleId IdType="pubmed">20699327</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal J., Zhang J., Kwinter D.M., Zhai J., Jia H., Jia J. and Zhu H. (2011) Nuclear localization sequence of FUS and induction of stress granules by ALS mutants. Neurobiol. Aging, 32, 2323 e2327&#x2013;2323 e2340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997923</ArticleId><ArticleId IdType="pubmed">20674093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D., Seki M., Tsunoda Y., Uchiyama H. and Suzuki N. (2011) Nuclear transport impairment of amyotrophic lateral sclerosis-linked mutations in FUS/TLS. Ann. Neurol., 69, 152&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">21280085</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D., Rodde R., Edbauer D., Bentmann E., Fischer I., Hruscha A., Than M.E., Mackenzie I.R., Capell A., Schmid B. &#xa0;et al. (2010) ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J., 29, 2841&#x2013;2857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924641</ArticleId><ArticleId IdType="pubmed">20606625</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D. and Haass C. (2013) Fused in sarcoma (FUS): an oncogene goes awry in neurodegeneration. Mol. Cell. Neurosci., 56, 475&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">23557964</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xfc;rkle A. (2001) In Brenner S. and Miller J.H. (eds), Encyclopedia of Genetics. Academic Press, New York, p. 1533.</Citation></Reference><Reference><Citation>Guo L., Kim H.J., Wang H., Monaghan J., Freyermuth F., Sung J.C., O&#x2019;Donovan K., Fare C.M., Diaz Z., Singh N. &#xa0;et al. (2018) Nuclear-import receptors reverse aberrant phase transitions of RNA-binding proteins with prion-like domains. Cell, 173, 677&#x2013;692.e620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911940</ArticleId><ArticleId IdType="pubmed">29677512</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofweber M., Hutten S., Bourgeois B., Spreitzer E., Niedner-Boblenz A., Schifferer M., Ruepp M.-D., Simons M., Niessing D., Madl T. and Dormann D. (2018) Phase separation of FUS is suppressed by its nuclear import receptor and arginine methylation. Cell, 173, 706&#x2013;719.e713.</Citation><ArticleIdList><ArticleId IdType="pubmed">29677514</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen T.J., Guo J.L., Hurtado D.E., Kwong L.K., Mills I.P., Trojanowski J.Q. and Lee V.M. (2011) The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun., 2, 252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3120096</ArticleId><ArticleId IdType="pubmed">21427723</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen T.J., Hwang A.W., Restrepo C.R., Yuan C.X., Trojanowski J.Q. and Lee V.M. (2015) An acetylation switch controls TDP-43 function and aggregation propensity. Nat. Commun., 6, 5845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407365</ArticleId><ArticleId IdType="pubmed">25556531</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin D.J., Cohen T.J., Grossman M., Arnold S.E., McCarty-Wood E., Van Deerlin V.M., Lee V.M. and Trojanowski J.Q. (2013) Acetylated tau neuropathology in sporadic and hereditary tauopathies. Am. J. Pathol., 183, 344&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3730769</ArticleId><ArticleId IdType="pubmed">23885714</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin D.J., Cohen T.J., Grossman M., Arnold S.E., Xie S.X., Lee V.M. and Trojanowski J.Q. (2012) Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain J. Neurol., 135, 807&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286338</ArticleId><ArticleId IdType="pubmed">22366796</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal J., Chen J., Na D.Y., Tichacek L., Barnett K.R. and Zhu H. (2019) The acetylation of lysine-376 of G3BP1 regulates RNA binding and stress granule dynamics. Mol. Cell. Biol., 39, e00052-19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6817755</ArticleId><ArticleId IdType="pubmed">31481451</ArticleId></ArticleIdList></Reference><Reference><Citation>Loughlin F.E., Lukavsky P.J., Kazeeva T., Reber S., Hock E.-M., Colombo M., Von Schroetter C., Pauli P., Cl&#xe9;ry A., M&#xfc;hlemann O. &#xa0;et al. (2019) The solution structure of FUS bound to RNA reveals a bipartite mode of RNA recognition with both sequence and shape specificity. Mol. Cell., 73, 490&#x2013;504.e496.</Citation><ArticleIdList><ArticleId IdType="pubmed">30581145</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Niu C., Ren J., Zhang J., Xie X., Zhu H., Feng W. and Gong W. (2013) The RRM domain of human fused in sarcoma protein reveals a non-canonical nucleic acid binding site. Biochim. Biophys. Acta, 1832, 375&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534766</ArticleId><ArticleId IdType="pubmed">23200923</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu C., Zhang J., Gao F., Yang L., Jia M., Zhu H. and Gong W. (2012) FUS-NLS/Transportin 1 complex structure provides insights into the nuclear targeting mechanism of FUS and the implications in ALS. PLoS One, 7, e47056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3466232</ArticleId><ArticleId IdType="pubmed">23056579</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Liu S., Liu G., Ozturk A. and Hicks G.G. (2013) ALS-associated FUS mutations result in compromised FUS alternative splicing and autoregulation. PLoS Genet., 9, e1003895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814325</ArticleId><ArticleId IdType="pubmed">24204307</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Zhang J., Kamelgarn M., Niu C., Gal J., Gong W. and Zhu H. (2015) Subcellular localization and RNAs determine FUS architecture in different cellular compartments. Hum. Mol. Genet., 24, 5174&#x2013;5183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643640</ArticleId><ArticleId IdType="pubmed">26123490</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamelgarn M., Chen J., Kuang L., Arenas A., Zhai J., Zhu H. and Gal J. (2016) Proteomic analysis of FUS interacting proteins provides insights into FUS function and its role in ALS. Biochim. Biophys. Acta, 1862, 2004&#x2013;2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5055831</ArticleId><ArticleId IdType="pubmed">27460707</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogryzko V.V., Schiltz R.L., Russanova V., Howard B.H. and Nakatani Y. (1996) The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell, 87, 953&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">8945521</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinert B.T., Narita T., Satpathy S., Srinivasan B., Hansen B.K., Scholz C., Hamilton W.B., Zucconi B.E., Wang W.W., Liu W.R. &#xa0;et al. (2018) Time-resolved analysis reveals rapid dynamics and broad scope of the CBP/p300 acetylome. Cell, 174, 231&#x2013;244.e212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6078418</ArticleId><ArticleId IdType="pubmed">29804834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasko L.M., Jakob C.G., Edalji R.P., Qiu W., Montgomery D., Digiammarino E.L., Hansen T.M., Risi R.M., Frey R., Manaves V. &#xa0;et al. (2017) Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature, 550, 128&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6050590</ArticleId><ArticleId IdType="pubmed">28953875</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dyke M.W. (2014) Lysine deacetylase (KDAC) regulatory pathways: an alternative approach to selective modulation. Chem. Med. Chem., 9, 511&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4105970</ArticleId><ArticleId IdType="pubmed">24449617</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitterman K.J., Anderson R.M., Cohen H.Y., Latorre-Esteves M. and Sinclair D.A. (2002) Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J. Biol. Chem., 277, 45099&#x2013;45107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12297502</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M., Kijima M., Akita M. and Beppu T. (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem., 265, 17174&#x2013;17179.</Citation><ArticleIdList><ArticleId IdType="pubmed">2211619</ArticleId></ArticleIdList></Reference><Reference><Citation>Mochizuki Y., Kawata A., Maruyama H., Homma T., Watabe K., Kawakami H., Komori T., Mizutani T. and Matsubara S. (2014) A Japanese patient with familial ALS and a p.K510M mutation in the gene for FUS (FUS) resulting in the totally locked-in state. Neuropathology, 34, 504&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">24841222</ArticleId></ArticleIdList></Reference><Reference><Citation>Syriani E., Morales M. and Gamez J. (2011) FUS/TLS gene mutations are the second most frequent cause of familial ALS in the Spanish population. Amyotroph Lateral Scler, 12, 118&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">21128870</ArticleId></ArticleIdList></Reference><Reference><Citation>Waibel S., Neumann M., Rabe M., Meyer T. and Ludolph A.C. (2010) Novel missense and truncating mutations in FUS/TLS in familial ALS. Neurology, 75, 815&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">20660363</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N., Aoki M., Warita H., Kato M., Mizuno H., Shimakura N., Akiyama T., Furuya H., Hokonohara T., Iwaki A. &#xa0;et al. (2010) FALS with FUS mutation in Japan, with early onset, rapid progress and basophilic inclusion. J. Hum. Genet., 55, 252&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">20224596</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan M., Talbot K. and Ansorge O. (2016) Pathogenesis of FUS-associated ALS and FTD: insights from rodent models. Acta Neuropathol. Commun., 4, 99&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5011941</ArticleId><ArticleId IdType="pubmed">27600654</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelkovnikova T.A., Peters O.M., Deykin A.V., Connor-Robson N., Robinson H., Ustyugov A.A., Bachurin S.O., Ermolkevich T.G., Goldman I.L., Sadchikova E.R. &#xa0;et al. (2013) Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice. J. Biol. Chem., 288, 25266&#x2013;25274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3757190</ArticleId><ArticleId IdType="pubmed">23867462</ArticleId></ArticleIdList></Reference><Reference><Citation>Scekic-Zahirovic J., Sendscheid O., El Oussini H., Jambeau M., Sun Y., Mersmann S., Wagner M., Dieterle S., Sinniger J., Dirrig-Grosch S. &#xa0;et al. (2016) Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss. EMBO J., 35, 1077&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4868956</ArticleId><ArticleId IdType="pubmed">26951610</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A., Lyashchenko A.K., Lu L., Nasrabady S.E., Elmaleh M., Mendelsohn M., Nemes A., Tapia J.C., Mentis G.Z. and Shneider N.A. (2016) ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nat. Commun., 7, 10465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4742863</ArticleId><ArticleId IdType="pubmed">26842965</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutskov V., Gerber D., Angelov D., Ausio J., Workman J. and Dimitrov S. (1998) Persistent interactions of core histone tails with nucleosomal DNA following acetylation and transcription factor binding. Mol. Cell. Biol., &#xa0;18, 6293&#x2013;6304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109216</ArticleId><ArticleId IdType="pubmed">9774646</ArticleId></ArticleIdList></Reference><Reference><Citation>Niaki A.G., Sarkar J., Cai X., Rhine K., Vidaurre V., Guy B., Hurst M., Lee J.C., Koh H.R., Guo L. &#xa0;et al. (2020) Loss of dynamic RNA interaction and aberrant phase separation induced by two distinct types of ALS/FTD-linked FUS mutations. Mol. Cell, 77, 82&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6943187</ArticleId><ArticleId IdType="pubmed">31630970</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann J.R., Gleixner A.M., Mauna J.C., Gomes E., DeChellis-Marks M.R., Needham P.G., Copley K.E., Hurtle B., Portz B., Pyles N.J. &#xa0;et al. (2019) RNA binding antagonizes neurotoxic phase transitions of TDP-43. Neuron, 102, 321&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang E.S. and Song S.B. (2017) Nicotinamide is an inhibitor of SIRT1 in vitro, but can be a stimulator in cells. Cell. Mol. Life Sci., 74, 3347&#x2013;3362.</Citation><ArticleIdList><ArticleId IdType="pubmed">28417163</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai Y.C., Greco T.M., Boonmee A., Miteva Y. and Cristea I.M. (2012) Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription. Mol. Cell. Proteomics, 11, 60&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3418843</ArticleId><ArticleId IdType="pubmed">22586326</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D., Li Y., Zhu K.S., Wang H. and Zhu W.-G. (2018) Advances in cellular characterization of the Sirtuin isoform, SIRT7. Front Endocrinol. (Lausanne), 9, 652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6253933</ArticleId><ArticleId IdType="pubmed">30510540</ArticleId></ArticleIdList></Reference><Reference><Citation>Michishita E., Park J.Y., Burneskis J.M., Barrett J.C. and Horikawa I. (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell, 16, 4623&#x2013;4635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1237069</ArticleId><ArticleId IdType="pubmed">16079181</ArticleId></ArticleIdList></Reference><Reference><Citation>Longworth M.S. and Laimins L.A. (2006) Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src. Oncogene, 25, 4495&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pubmed">16532030</ArticleId></ArticleIdList></Reference><Reference><Citation>McManus K.J. and Hendzel M.J. (2001) CBP, a transcriptional coactivator and acetyltransferase. Biochem. Cell. Biol., 79, 253&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">11467739</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundby A., Lage K., Weinert B.T., Bekker-Jensen D.B., Secher A., Skovgaard T., Kelstrup C.D., Dmytriyev A., Choudhary C., Lundby C. and Olsen J.V. (2012) Proteomic analysis of lysine acetylation sites in rat tissues reveals organ specificity and subcellular patterns. Cell Rep., 2, 419&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4103158</ArticleId><ArticleId IdType="pubmed">22902405</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahoo P.K., Lee S.J., Jaiswal P.B., Alber S., Kar A.N., Miller-Randolph S., Taylor E.E., Smith T., Singh B., Ho T.S.-Y. &#xa0;et al. (2018) Axonal G3BP1 stress granule protein limits axonal mRNA translation and nerve regeneration. Nat. Commun., 9, 3358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105716</ArticleId><ArticleId IdType="pubmed">30135423</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrusiak M.G., Sharifnia P., Lyu X., Wang Z., Dickey A.M., Wu Z., Chisholm A.D. and Jin Y. (2019) Inhibition of axon regeneration by liquid-like TIAR-2 granules. Neuron, 104, 290&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6813885</ArticleId><ArticleId IdType="pubmed">31378567</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S. and Gitler A.D. (2019) Axons gonna ride &#x2018;til they can&#x2019;t no more. Neuron, 104, 179&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">31647889</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyzack G.E., Luisier R., Taha D.M., Neeves J., Modic M., Mitchell J.S., Meyer I., Greensmith L., Newcombe J., Ule J. &#xa0;et al. (2019) Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis. Brain, 142, 2572&#x2013;2580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6735815</ArticleId><ArticleId IdType="pubmed">31368485</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson C.J., Hossain M.M., Richardson J.R. and Aleksunes L.M. (2012) Inflammatory regulation of ATP binding cassette efflux transporter expression and function in microglia. J. Pharmacol. Exp. Ther., 343, 650&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3500534</ArticleId><ArticleId IdType="pubmed">22942241</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal J., Kuang L., Barnett K.R., Zhu B.Z., Shissler S.C., Korotkov K.V., Hayward L.J., Kasarskis E.J. and Zhu H. (2016) ALS mutant SOD1 interacts with G3BP1 and affects stress granule dynamics. Acta Neuropathol., &#xa0;132, 563&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5023729</ArticleId><ArticleId IdType="pubmed">27481264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuang L., Kamelgarn M., Arenas A., Gal J., Taylor D., Gong W., Brown M., St. Clair D., Kasarskis E.J. and Zhu H. (2017) Clinical and experimental studies of a novel P525R FUS mutation in amyotrophic lateral sclerosis. Neurol. Genet., &#xa0;3, e172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5546284</ArticleId><ArticleId IdType="pubmed">28812062</ArticleId></ArticleIdList></Reference><Reference><Citation>Goddard T.D., Huang C.C., Meng E.C., Pettersen E.F., Couch G.S., Morris J.H. and Ferrin T.E. (2018) UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci., 27, 14&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5734306</ArticleId><ArticleId IdType="pubmed">28710774</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>